Sai Parenterals Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Margin expansion despite disruption: Gross margin jumped 370 bps QoQ to 41.8% as raw material price revision lags began unwinding, even while air freight costs from West Asian supply disruptions ate into EBITDA.
• FY27 guidance held with confidence: Management reiterated ₹750 crores revenue at ~17% EBITDA margin, calling Q1 ahead of plan on the 45:55 H1/H2 split and dismissing next-quarter challenges as one-time.
• IPO funds redeployed into two acquisitions: ₹101.85 crores of unutilized IPO proceeds will shift toward a 60% stake in Saicriti (critical care injectables facility under construction) and a 60% stake in Prathyak Laboratories (established R&D center).
• EBOS renewal locks in Australian base: The exclusive OTC supply agreement with EBOS Group was renewed for 7.5 years at AUD 20.2 crore, with 12 new products added annually and a 3-year extension option to 2036.
• What to watch next quarter: Whether the full raw material cost recovery actually flows through the contract book in Q2, progress on the Saicriti and Prathyak shareholder approvals, and any revision to FY27 guidance.

Margin Performance & Cost Recovery

• Gross margin mechanics: Contracts carry a 90–120 day window between price revision notification and realization; that lag is now beginning to unwind in the company's favor, lifting gross margin to 41.8% from 38.1% QoQ. Recovery of raw material cost increases remains partial at this stage.
• EBITDA held up on a lower base: EBITDA margin improved 50 bps QoQ to 14.9% despite lower revenue and despite absorbing elevated air freight cost in Australia.
• Air freight was the swing factor: The West Asian situation delayed consignments from the Indian contract manufacturing network into Australia, an industry-wide disruption. Noumed moved available inventory by air rather than sea to protect customer commitments, which carried a cost; absent those constraints, margins would have been better.
• Service continuity protected: Service level agreements and minimum supply obligations to pharmacy chains were all met despite the disruption, releasing the company from any severe penalties related to continuity of supply.
• Q1 shortfall was narrow and transient: EBITDA came in 2% below plan only because of supply disruptions and air freight at Noumed; that has now gone.
• Standalone leverage: Standalone revenue grew 175% YoY with EBITDA margin expanding 890 bps YoY, primarily on operating leverage.

Anil K K: "And you can clearly see a visibility of the 750 and 17% crossing on very smoothly and comfortably."

Acquisitions & IPO Fund Redeployment

• Board approved variation in IPO objects: ₹83.83 crores originally earmarked for Unit-1 and Unit-2 capacity expansion, plus ₹18.02 crores for a new R&D center, will be redeployed toward majority stakes in two operating pharmaceutical assets, aggregating ₹101.85 crores, subject to shareholder approval.
• Saicriti is a project under construction, not an established business: Sai proposes to acquire 60% of Saicriti Pharma Private Limited for ₹83.83 crores. Saicriti was formed to construct a critical care injectable facility at Gummadidala on a 15,000 square yard site; approvals are in place and civil work is already underway. The facility is being built to European GMP and USFDA standards with capability in complex injectables, lyophilisation and GLP, plus general injectable capacity.
• Saicriti brings an existing franchise: Saicriti's existing domestic critical care franchise of ~₹52 crores will in due course be manufactured from the same new site.
• Prathyak adds R&D depth: The dedicated R&D subsidiary proposes to acquire 60% of Prathyak Laboratories for ₹15 crores. Prathyak operates an established R&D center at Genome Valley, Hyderabad with 3 years of operating history, 65 personnel including 28 research scientists, a pipeline of 150 SKUs across 86 molecules, and proven capability in lyophilised, liposomal and nano-based complex injectables and oncology injectables.
• Prathyak timeline: Transaction expected to complete on or before 30th September; it will become a step-down subsidiary named Sai Prathyak.
• Prathyak activates immediately: From day one after acquisition, R&D will start activity for Sai and Noumed; all developments needed at Sai level and Noumed will be taken up on the first day.
• Saicriti economics: Sai will get products manufactured in Saicriti for existing injectable sales; Critigen will also use the facility; exports and CMO will happen directly from Saicriti. OPEX breakeven is expected in the first year itself.

Anil K K: "I want to be precise on one point that anticipate you may inquire. This is an investment into a project under construction. It is not the purchase of an established business."

Australia & Noumed

• EBOS renewal is locked in: The exclusive OTC supply agreement with EBOS Group (TerryWhite Chemmart and Pharmacy Choice) was renewed on 1st July 2026. Valued at AUD 20.2 crore (~₹1,300 crore at \$1 to ₹64.5), exclusive for 7.5 years, ~AUD 2.7 crore per year, with a 3-year extension option to 2036. The agreement is built to grow with the addition of 12 new products every year.
• Order value covers existing portfolio only: The AUD 20.2 crore order covers the existing supply portfolio; the 12 NPD products are up and above the order value.
• NPD development split: First 24 products identified between Noumed and customer; Sai is developing 8 of these with 6 already started; 4 products are exclusive supply contracts for the Australasian area; the remaining are developed through a strategic partnership with Catalent (US) based on soft gels.
• Adelaide facility progressing: Internal builds (clean rooms, HVAC, water and power rings, drain rings) and equipment are complete; all equipment is now in process of order and delivery. Physical completion targeted for January 2027; TGA licensing inspection anticipated by 31st March 2027; Phase 1 manufacturing expected from April 2027.
• Validation timeline: Validation work of first packing lines runs through December and January; completion of validation in February; TGA licensing and inspection by March 2027.
• Local manufacturing cuts inventory burden: Local manufacturing is expected to reduce inventory holding from 9–10 months to 5–6 months.
• Noumed shifts to internal sourcing: Noumed will withdraw from third-party sourcing and utilize the internal network with Sai Parenterals for self-manufacturing.
• Forecasting improving: At present stage, forecasting on some molecules is increased by around 8% overall in the market.
• More wins expected: More order wins of TerryWhite EBOS size are expected over the next one year.
• CMO pipeline exists but undisclosed: Several CMO opportunities from multinationals for the new Australia plant are in very serious conversation; management cannot elaborate further.

Mark Thulborne: "The pharmacy chains own the brands, but we own all the registration and hold the IP. They do no manufacturing. That is precisely the gap that Noumed fills."

Facility Expansion & Regulatory Context

• Telangana relocation order: A government order in February-March 2026 requires red and orange category units within the outer ring road to relocate outside within 3 years; no further permissions for upgradations in existing facilities.
• Saicriti facility completion: April 2027.
• Saicriti market sequence: Will start with ROW markets; first target Europe, then Southeast Asia, Latin America, Middle East. The US FDA option will be reviewed at a later date; given a chance, the company will go with US FDA after the facility is completed.
• Saicriti USFDA qualification: The facility will qualify for US FDA with another 50% upgradation in manufacturing outcome.
• Injectable exports gap: Unit-1 and Unit-2 are majorly doing the domestic market; the company is not exporting injectables to ROW or European markets because existing facilities are not qualified. Current exports are entirely oral dosage formulations and Cephalosporins.
• Australian facility funding complete: Company infused AUD 0.18 crore ~6 weeks ago; Board approved balance AUD 0.17 crore for deployment within coming weeks. Funding of AUD 5.3 crore for Australian programs is now complete.

US Subsidiary & International Structure

• US subsidiary incorporated: Board approved incorporation of a subsidiary in the United States, held as a step-down subsidiary through Sai Parenterals PTE Singapore. The entity is created to support evaluation of entry into the US market; evaluation is at a preliminary stage.
• Singapore entity role: Established as an investment arm; used for acquisition of Noumed Australia; tax benefits between Australia and Singapore.
• US strategy is undecided: Management said it is too premature to discuss whether the US entity will initially be a sales/commercial platform or eventually local manufacturing, and when US business starts contributing meaningfully.
• US tax evaluation pending: US is very preliminary; tax benefits have not yet been evaluated; the company will evaluate and revert as progress is made.

Anil K K: "When the opportunity is seized and our evaluation gets completed, then obviously we will come to the market and we will declare that. So as of now, it is just a subsidiary formation to validate the opportunities going forward."

Balance Sheet & Debt

• Debt reduced sequentially: Debt reduced to ~₹310 crores from ~₹319 crores in March, because ₹50 crores of IPO-proceeds loans were repaid, offset by certain loans taken for the Noumed acquisition CAPEX plan.
• FY27 is peak debt year: FY27 is expected to be the peak debt year because the ongoing CAPEX and acquisition program is completing; de-leveraging begins from FY28 as assets begin contributing to earnings and cash flows.
• Group debt trajectory: Group-level debt (excluding new projects) is fairly well-placed and will only keep going down as debts are repaid; the Saicriti acquisition will have additional debt based on a 60%-40% equity-debt ratio; debt equity ratio should be in the range of 0.6 times.
• Peak debt not quantified: An analyst asked what peak debt level to consider over the next 2-3 years and the intended de-leveraging path; management provided current debt figures and the debt-equity ratio range but did not give a specific peak debt number for the next 2-3 years including new initiatives.
• Consolidated PAT decline: Sequential decline in PAT versus ₹13.2 crores in Q4 FY26 reflects the lower revenue base and a normalized tax charge in Q1 FY27.

Guidance & Commitments

Key Metrics